Last reviewed · How we verify

Placebo matched to FTC/TDF — Competitive Intelligence Brief

Placebo matched to FTC/TDF (Placebo matched to FTC/TDF) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Infectious Disease.

phase 3 Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matched to FTC/TDF (Placebo matched to FTC/TDF) — Merck Sharp & Dohme LLC. This is a placebo control arm matched to the active combination of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), containing no active antiretroviral agents.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo matched to FTC/TDF TARGET Placebo matched to FTC/TDF Merck Sharp & Dohme LLC phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matched to FTC/TDF — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matched-to-ftc-tdf. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: